8-K: Sera Prognostics Unveils PreTRM Test for Preterm Birth

Sera Prognostics announces strong clinical validation and commercialization plans for its PreTRM test, aiming to redefine pregnancy care and reduce the burden of preterm birth.

Summary

• Sera Prognostics, Inc. (the Company) posted a new investor presentation on September 5, 2025, which was also shared at the H.C. Wainwright 27th Annual Global Investment Conference.
• The Company's vision is to become a global leader in high-value women's health diagnostics, focusing on a holistic approach to improve health for moms and babies while enhancing healthcare economics.
• The PreTRM test is a proteomics-based blood test designed for early prediction of spontaneous preterm birth risk, and is the only clinically validated test available for this purpose, verified by 8 independent clinical studies.
• As of June 30, 2025, the Company reported $108.5 million in cash, cash equivalents, and marketable securities, which is projected to extend through 2028, supporting commercialization efforts with an approximate $30 million annual operating spend.
• The US faces a significant premature birth problem, with rates rising from 9.4% to 10.4% between 2013-2023, and NICU admissions increasing from 8.7% to 9.8% from 2016-2023.
• Premature birth incurs substantial economic costs, estimated at $25.2 billion annually in the US, with extremely premature births costing up to $344,355 compared to $4,165 for full-term deliveries.
• Traditional screening methods miss 81% of spontaneous preterm births, highlighting a critical unmet need that PreTRM aims to address by identifying risk before symptoms manifest.
• The PreTRM test measures specific proteins (IGFBP4 and SHBG) associated with preterm birth risk, with results delivered in an average of five days from a blood sample collected between 18 0/7 and 20 6/7 weeks of gestation.
• The PRIME Randomized Controlled Trial (November 2020 December 2023) achieved its primary endpoint, leading to early termination, and demonstrated significant improvements in neonatal outcomes.
• The AVERT Historically Controlled Trial (June 2018 September 2020) also showed positive results, with both studies indicating that PreTRM-guided interventions lead to lower neonatal morbidity and mortality, decreased NICU admissions, and increased gestational age.
• A health economic model, to be presented at ISPOR EUROPE 2025 in November, suggests potential savings of $4,234 per person screened, with a test cost of $750 and intervention cost of $1,200.

Sentiment

Score: 9

Explanation: The filing presents highly positive clinical trial results for its flagship product, a strong cash position, and a clear commercialization pathway addressing a significant unmet medical need and economic burden. The data suggests a strong competitive advantage and potential for rapid market adoption.

Positives

• The PreTRM test is the only clinically validated test available for early prediction of premature birth, supported by 8 independent clinical studies.
• Strong cash position of $108.5 million as of June 30, 2025, providing runway through 2028 to reach revenue inflection point.
• The PRIME Randomized Controlled Trial achieved its primary endpoint, leading to early termination, indicating highly positive results.
• Clinical studies (PRIME and AVERT) demonstrated significant improvements: 20% reduction in neonatal morbidity and mortality, 22% decrease in NICU admissions, 8% reduction in NICU length of stay, and 35% decrease in odds of delivery before 35 weeks.
• The PreTRM test is highly efficient, requiring only 4 moms to be screened to prevent 1 NICU day, which is more than 3x more efficient than ultrasound screening.
• The Company is positioned for commercial inflection, with ongoing progress in engaging Medicaid plans and a pilot program already launched in one state.
• Addresses a significant market opportunity with the potential to reduce the $25.2 billion economic cost of preterm birth in the US.
• Digital partnership with EverydayHealth reaches 80% of US pregnant women, enhancing education and awareness for the PreTRM test.

Negatives

• The US has a 'D Rating' from March of Dimes regarding premature birth, indicating a national challenge.
• Preterm birth rates in the US rose from 9.4% to 10.4% from 2013-2023, and NICU admissions increased from 8.7% to 9.8% from 2016-2023, highlighting a worsening trend.
• Traditional screening methods are largely ineffective, missing 81% of spontaneous preterm births, leading to high healthcare costs associated with premature deliveries.

Risks

• The presentation contains forward-looking statements that involve substantial risks and uncertainties, as detailed in the company's Registration Statement on Form S-1, most recent Annual Report on Form 10-K, and/or subsequent Forms 10-Q under the heading 'RISK FACTORS'.

Future Outlook

The Company is entering a commercialization stage for the PreTRM test, with a focus on achieving broad market adoption, guideline inclusion, and payer coverage. Key initiatives include targeted geographic investment, engaging Medicaid plans through pilot programs, expanding institutional conversations, and building density of adoption among priority physicians. Full PRIME data publication and sub-analyses are expected soon, further supporting these efforts.

Management Comments

• Our vision is to become a global leader in high-value women's health diagnostics.
• We are redefining pregnancy care to reduce the burden of preterm birth.
• We can do better for women's health. TOGETHER.

Industry Context

The US faces a significant and worsening premature birth problem, with rising rates and increased neonatal intensive care unit (NICU) admissions. Traditional screening methods are largely ineffective, missing a substantial majority of spontaneous preterm births. This creates a massive economic burden and a critical unmet medical need for accurate, early predictive diagnostics, positioning Sera Prognostics' PreTRM test to address a major public health challenge.

Comparison to Industry Standards

• The PreTRM test demonstrates superior efficiency with a Number Needed to Screen (NNS) of 4 to prevent 1 NICU day, significantly outperforming current methods.
• This NNS of 4 is more than 3x more efficient than Transvaginal Ultrasound Cervical Length + Progesterone (NNS 150) for preventing NICU admission.
• The PreTRM test is also more efficient than the Glucose screening test (NNS 50) for preventing NICU admission.

Stakeholder Impact

• Shareholders: Potential for significant value creation through successful commercialization of a clinically validated product addressing a large market.
• Patients (Moms and Babies): Improved health outcomes, reduced risk of spontaneous preterm birth, lower neonatal morbidity and mortality, and decreased NICU admissions and length of stay.
• Healthcare Providers: Enhanced ability to identify high-risk pregnancies early, clear guidance on managing higher-risk patients, and seamless integration of the PreTRM test into clinical workflows.
• Payers (Insurance Companies, Medicaid): Potential for substantial healthcare cost savings by reducing the incidence and severity of preterm birth complications and associated NICU stays.
• Employees: Opportunities for growth and expansion as the company scales its commercial and research operations.

Next Steps

• Full PRIME data publication and publication of sub-analyses are coming soon.
• Continue ongoing progress in engaging Medicaid plans in targeted states, with expansion of pilot programs.
• Continue institutional (large hospitals and IDN) conversations, leveraging PRIME data.
• Develop individualized programs tailored to local Medicaid populations and institutions.
• Focus sales efforts on priority target physicians and early adopters.
• Add sales and research resources in key geographies to educate and encourage adoption.
• Present Health Economic Data model at ISPOR EUROPE 2025 in November.

Key Dates

Recommendation

The company has presented compelling clinical evidence for its PreTRM test, demonstrating significant improvements in neonatal outcomes and substantial healthcare cost savings. With a strong cash runway through 2028 and a clear commercialization strategy targeting a large unmet medical need, the company appears well-positioned for significant revenue acceleration. The positive trial results (PRIME and AVERT) and the unique, clinically validated nature of the product suggest a strong competitive advantage and potential for rapid market adoption and favorable reimbursement.

Keywords

Sera Prognostics, PreTRM, preterm birth, pregnancy care, diagnostics, women's health, proteomics, clinical validation, NICU, maternal health, neonatal outcomes, SEC filing, investor presentation